Articles tagged with Breast Cancer
A new AI model can identify certain stages of ductal carcinoma in situ (DCIS), a type of pre-invasive breast cancer, that are likely to progress to invasive cancer. The model uses imaging and machine learning to analyze tissue samples and determine the stage of DCIS based on cell arrangement and organization.
Researchers analyzed collision-type mixed ductal-lobular breast cancers and found that IDC and ILC regions had distinct gene expression profiles. The study reveals tremendous variation within this already highly variable disease, highlighting the need for personalized treatments.
The study reveals that non-coding RNAs, including microRNAs, long non-coding RNAs, and circular RNAs, play a crucial role in regulating the Notch signaling pathway in breast cancer. These molecules can modulate gene expression and affect cancer cell proliferation, invasion, and metastasis.
A new compound developed by researchers at MUSC Hollings Cancer Center has shown promise in improving response to chemotherapy in preclinical models. The compound inhibits the protein lysyl oxidase, preventing it from producing a stiff environment around tumors and allowing drugs to penetrate better.
The UVA School of Engineering and Applied Science has been awarded a collective $10 million in research grants by Susan G. Komen, including a $100,000 grant for doctoral student Catalina Alvarez Yela's work on triple negative breast cancer.
Researchers from Drexel University have identified two compounds, AD-5584 and AD-8007, that selectively kill cancer cells and block tumor growth by targeting a key metabolic enzyme in cancer cells. These findings show early success in shrinking breast cancer tumors in brain metastases and offer hope for more effective therapies.
A new study found that an electronic health record (EHR)-based nudge intervention significantly decreased low-value axillary surgery in older women with clinically node-negative, HR+/HER2− breast cancer. The user-friendly intervention could be beneficial for other practice settings or patient populations.
Researchers developed an electronic health record nudge to remind surgeons about the risks of lymphedema and potential overtreatment. The intervention led to a 49.3% reduction in sentinel lymph node biopsy procedures among eligible patients.
A Mayo Clinic study reveals that current genetic screening protocols fail to detect notable numbers of people carrying hereditary breast and ovarian cancer syndrome and Lynch syndrome mutations. The study identified 550 carriers of these mutations, with half being previously unaware of their risk.
A retrospective cohort study found hormone-modulating therapy protected against Alzheimer's disease and related dementias in postmenopausal women with breast cancer. The protective effect varied by age and race, with greater benefit for Black women under 75.
A new study from the University of Michigan Health Rogel Cancer Center found that nearly three-quarters of patients who were eligible for genetic testing at diagnosis received it over the study period. Those who got testing and found they had a genetic variant were most likely to talk with their family about the results.
A new study published in JAMA Network Open found that hormone modulating therapy (HMT) used to treat breast cancer was associated with a 7% lower risk of developing Alzheimer's disease and related dementias. The protective effect of HMT decreased with age, particularly for women over 80.
Researchers discuss HER2 in breast cancer, highlighting the prognostic and predictive factors. They found an independent positive prognostic effect of HER2-low compared to HER2-zero in early breast cancer, challenging the long-held view that HER2-negative tumors do not benefit from trastuzumab-based therapy.
A nationally representative US survey found that women aged 39-49 who received a decision aid describing the benefits and harms of breast cancer screening were more likely to delay or forego screening. The study suggests that providing accurate information may change intention to screen for some women, particularly those with higher br...
Researchers at Linköping University created a tool to predict risk of persistent side effects in breast cancer patients treated with taxane drugs. The model uses genetic characteristics to forecast the risk of nerve damage, which can be used to adapt treatment and improve patient outcomes.
Researchers have identified a shared molecular mechanism between pregnancy and cancer that suppresses the immune system. Progesterone was found to play a key role in this process, with blocking its signaling slowing down cancer growth in mice and activating the immune response.
A new Finnish study from University of Turku shows that already a 30-minute exercise can increase the proportion of tumor-killing white blood cells in the bloodstream of breast cancer patients. The amount of several different white blood cell types increased during exercise, with cytotoxic T cells and natural killer cells rising the most.
A recent study published in Plastic and Reconstructive Surgery found that American Indian/Alaska Native women have consistently lower rates of breast reconstruction after mastectomy compared to non-Hispanic White women. The disparity persists despite an upward trend in reconstruction rates, with AI/AN women being nearly half less likel...
A new study has identified potential cancer drivers hidden in so-called 'junk' regions of DNA, which could lead to early diagnosis and new treatments. The discovery reveals mutations in previously overlooked regions of the genome that may contribute to the formation and progression of at least 12 different cancers.
Researchers at Osaka University have developed molecules that can correct improper splicing of a vital tumor suppressor gene in neuroendocrine cancers. The study demonstrates that these splice-switching oligonucleotides can significantly reduce viable cancer cells and tumor size in mice, suggesting a novel therapeutic approach for intr...
Researchers at Karolinska Institutet developed nanorobots that target and kill cancer cells using a 'kill switch' activated in low pH environments. The study achieved a 70% reduction in tumour growth in mice, paving the way for further investigation into its potential as a cancer treatment.
Researchers have discovered compounds that convert the Bcl-2 protein, which protects cancer cells, into a tumor killer. The findings open the door to promising therapies for breast cancer and other malignancies that rely on Bcl-2 to evade treatment and develop drug resistance.
A clinical trial found that trastuzumab emtansine (T-DM1) is highly effective in preventing stage 1 HER2-positive breast cancer from recurring in patients. The treatment significantly reduced the risk of recurrence and improved patient-reported outcomes compared to chemotherapy and trastuzumab.
A new study from the University of Copenhagen reveals that AI has helped detect significantly more cases of breast cancer and reduce radiologist workloads. The AI system has been used to analyze tens of thousands of X-rays every year, resulting in a 12% increase in detected cases, including more small tumours of one centimetre or less.
Research by UCLA Health confirms that Tai Chi reduces inflammation and improves anti-viral defenses in breast cancer survivors, while cognitive behavioral therapy shows greater increases in anti-viral gene transcripts. The study found significant reductions in inflammatory biomarkers among Tai Chi participants.
A study by Ohio State University researchers found that chemotherapy disrupts the gut microbiome in breast cancer patients, leading to cognitive decline and increased inflammation. The research suggests that targeting the gut microbiome may improve behavioral side effects of chemotherapy.
A novel inhibitor HVH-2930 targeting heat shock protein 90 (HSP90) demonstrates efficacy against drug-resistant breast cancer cells. It selectively downregulates HER2 signaling, crucial for breast cancer progression, without triggering the heat shock response.
A pooled analysis of three randomized trials found that acupuncture significantly reduced hot flashes and hormonal side effects in women with stage 0-III breast cancer. The study showed that 64% of participants experienced improvements in hot flashes, and acupuncture also improved quality of life.
A study published in Journal of Clinical Oncology found that socioeconomic status significantly impacts the quality of life of women diagnosed with breast cancer. Women from lower socioeconomic backgrounds experience more pronounced physical and psychological side effects, despite similar medical treatment.
Finnish researchers found that blocking the DUSP6 protein can significantly improve treatment outcomes in experimental models by preventing dormant breast cancer cells from waking up. This discovery provides new insights into breast cancer recurrence and offers a potential basis for effective combination therapy.
Families with germline CDH1 P/LP variants show a cumulative risk of gastric cancer between 7-10% and breast cancer in female carriers at 37%
Researchers at Weill Cornell Medicine developed an artificial intelligence-powered method for detecting tumor DNA in blood, showing high sensitivity and accuracy in predicting cancer recurrence. The technology, called MRD-EDGE, can detect subtle patterns in sequencing data to distinguish between cancer and non-cancerous signals.
A cohort study found that neighborhood deprivation is associated with increased breast cancer mortality in non-Hispanic white women, but not in non-Hispanic Black women. Factors beyond those explored may contribute to the disparity in breast cancer mortality among Black women.
A comparative study between FAPI and 18F-FDG PET/CT shows that FAPI PET/CT is more accurate in staging newly diagnosed breast cancer patients, with 19.8% being restaged due to its high sensitivity. This could lead to optimized management plans and improved patient outcomes.
A study led by researchers from the University of Arizona Cancer Center identified a biological mechanism that could lead to more effective treatments for breast cancer that has metastasized to the brain. By targeting the autophagy pathway, the researchers were able to disrupt breast cancer cells' ability to form brain metastases.
A recent study from the Women's Health Initiative found that both obesity and metabolic syndrome increase breast cancer risk, but in distinct ways for different subtypes. The research highlights the importance of controlling waist circumference and metabolic conditions to reduce breast cancer risk.
A study has shown that a potassium ion channel located in mitochondria rewires metabolism in breast cancer cells, promoting tumor growth. The channel, BKCa, is linked to the Warburg effect, a metabolic hallmark of cancer, by causing increased lactate secretion and hydrogen peroxide levels.
Researchers discovered that a mutation in the TREX1 gene causes catastrophic DNA damage, leading to premature aging and organ damage. The study found that targeting TREX1 could have broad implications for treating many human diseases linked to aging.
A study published in Radiology found that AI significantly improved breast cancer detection and reduced false-positive findings. The AI system detected more cancers while lowering the rate of unnecessary recalls, reducing radiologist workload by 33.4%.
Researchers found that tumor-associated macrophages respond to physical properties of fibrosis by synthesizing injury-associated collagens, resulting in metabolic changes that suppress CTL function. This provides an alternative explanation for why anti-tumor immunity is impaired in fibrotic solid tumors.
A study published in Frontiers in Oncology reveals breast cancer incidence has surged in oil-rich Gulf countries, with unique clinical and pathological features. The disease is attributed to a combination of menstrual cycle, hereditary factors, weaning children earlier than expected, hormonal treatment, obesity, and use of contraceptives.
Research links early menopause to higher risks of breast and ovarian cancer in women. Second-degree relatives also show increased risks for colon, prostate, and testicular cancers.
A quality improvement analysis found that many US residents live within 30 miles of a clinical trial site, highlighting disparities in access. The study highlights concerns about equity and fairness in healthcare resource distribution, particularly for marginalized communities.
A new study by Indiana University researchers found that Black patients with breast cancer who receive docetaxel instead of paclitaxel have significantly lower rates of taxane-induced peripheral neuropathy (TIPN). This toxicity can lead to debilitating numbness, tingling, and pain in the hands and feet, impacting chemotherapy doses.
A new study by ECOG-ACRIN Cancer Research Group aimed to address disparities in breast cancer care for Black patients. The trial found that tailoring research to the needs of underserved groups is effective, with docetaxel showing lower rates of peripheral neuropathy and dose reductions compared to paclitaxel.
A study found that nearly 20% of breast cancer survivors experience excess weight gain of more than 10% over six years. Factors associated with this weight gain include lower body weight, younger age, hormone-positive breast cancer, and certain genetic mutations.
Researchers at Dana-Farber Cancer Institute have reported encouraging results from three separate studies on treatments for central nervous system lymphoma, breast cancer, and glioblastoma. CAR T-cell therapy showed a 94% overall response rate in patients with CNS lymphoma, while an antibody-drug conjugate plus checkpoint inhibitor imp...
A Stanford Medicine study found that inherited gene sequences predict breast cancer type and mortality. The research challenges the dogma of random mutations, instead highlighting the role of germline genome factors in tumor development.
A team of researchers from Xi'an Jiaotong-Liverpool University has engineered a short sequence of artificial DNA to target the mutant protein p53-R175H, linked to lung, colorectal, and breast cancers. The new molecule, dp53m, inhibits cancer cell growth and increases sensitivity to chemotherapy agent cisplatin.
Researchers from Mass General Cancer Center are set to present key findings on palliative care delivery via telehealth versus in-person for patients with advanced lung cancer. The presentations also cover advances in colorectal and breast cancer treatments, as well as results from a phase 1b/2 study on a novel BRAF inhibitor.
Researchers discovered a previously unknown biological process through which breast tumor cells develop resistance to standard treatment. The study found that targeting the degradation of both HER2 and EGFR receptors can overcome drug resistance in HER2-positive breast cancer models.
Sharon Giordano and Richard Gorlick will be honored with Special Awards at the 2024 American Society of Clinical Oncology Annual Meeting for their dedication to improving cancer treatment and patient outcomes. Their research has made significant contributions to the field of oncology, with a focus on breast cancer and pediatric oncology.
The COVID-19 pandemic led to a decline in breast cancer screenings, particularly among older and racial minority women. A study analyzing real-world electronic health records found that follow-up screening rates decreased significantly during the pandemic, resulting in missed opportunities for early detection and treatment.
A recent study by Dr. Zhaohua Jiang successfully demonstrated VLNT's effectiveness in reconnecting the lymphatic system and improving patient outcomes. The procedure involves transplanting healthy lymph nodes into the affected area, promoting regeneration and reconnection of lymphatic vessels.
Researchers explore nanoparticle-based therapies to specifically target lymphatic metastasis in breast cancer, providing a promising solution for patient treatment. Nanoparticles deliver drugs directly to tumors, targeting cancer cells to destroy them or slow their growth, while also enhancing the immune response.
A study analyzing data from the National Cancer Database found that patients receiving care at minority-serving hospitals were 17% less likely to receive definitive treatment for breast cancer and up to 31% less likely for prostate, lung, and colon cancers. Improving treatment rates could lead to additional patient outcomes.
Researchers at Baylor College of Medicine identified PKMYT1, a protein kinase associated with resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancers. The study found that combining a PKMYT1 inhibitor with chemotherapy drug gemcitabine selectively reduced the viability of resistant cancer cells.
A recent study published by Dana-Farber Cancer Institute found that nearly 200 young women who tried to conceive after breast cancer treatment were able to become pregnant and have a live birth. Egg/embryo freezing before treatment was associated with a higher live birth rate, while older participants had lower rates.
SWOG Cancer Research Network will share results of their work in 30 presentations at the 2024 American Society of Clinical Oncology Annual Meeting, May 31 – June 4 in Chicago. The research focuses on improving cancer treatments and reducing devastating side effects.
Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.